急性前骨髄球性白血病および成人T細胞性白血病リンパ腫に対する亜ヒ酸療法施行時のヒ素の体内動態

概要

論文の詳細を見る
Arsenic trioxide (As_2O_3) chemotherapy is now used for the treatment of relapsed patients with acute promyelocytic leukemia (APL) and adult T-cell leukemia (ATL) in the First Internal Medicine Department of Fukuoka University Hospital. In order to adjust the dosage, we studied the pharmacokinetics of As_2O_3 when administered intravenously to patients with APL and ATL. Plasma arsenic concentrations were measured by gas-chromatograph/mass-spectrometry (GC/MS). The maximum arsenic concentration (Cmax) and area under the curve (AUC) were 8.3±0.8 (μM) and 61.7±4.2 (μM・hr) on the first day and 8.6±0.7 (μM) and 63.5±6.6 (μM・hr) on the twentieth day of treatment, respectively. Apparent distribution volume and total body clearance were 0.14±0.02 (L/kg) (range 0.12-0.18) and 0.036±0.004 (L/hr/kg) (range 0.030-0.039), respectively. From these results, we conclude that the pharmacokinetic behavior of As_2O_3 did not alter in continuous administration, and the variation in pharmacokinetic parameters was extremely small among the patients.
日本医療薬学会の論文
2004-07-10